What Stopping a GLP-1 Actually Costs
Most coverage of stopping GLP-1s focuses on the health question. This page focuses on the financial one: what the newest 2026 research actually says about regain, and - the part that rarely gets covered - what restarting costs you in re-titration time and insurance friction, on top of whatever weight comes back.
What 2026 research actually shows about regain
Oxford researchers analyzed 9,341 participants across 37 studies and found weight regain after stopping a GLP-1 runs roughly 4x faster than after stopping a behavioral diet/exercise program - about 0.4 kg/month on average, with weight returning to baseline in 1.7 years on average. Cardiometabolic benefits (blood pressure, lipids) reversed even sooner than the weight itself.
A separate meta-regression across 48 studies modeled the actual shape of the regain curve: about 60% of lost weight back by 1 year, decelerating toward a long-term plateau around 75% of the original loss regained - meaning roughly 25% of the weight lost tends to stay off indefinitely, even without any further treatment.
A study of nearly 8,000 patients who stopped semaglutide or tirzepatide found much smaller regain in actual practice - about 0.5% of body weight at 1 year for the obesity-treatment group (55% gained some weight, 45% held steady or kept losing). The gap versus the trial data is explained by what people actually did after stopping: 20% restarted the same drug, 27% switched to a different obesity medication, and 14% moved to lifestyle-only management with a provider. Trial data assumes nothing changes after stopping; in practice, something usually does.
None of this is a recommendation to stop or continue - that decision belongs to you and your prescriber. It is context for the cost decisions below, which is what this site covers.
The part nobody prices out: what restarting actually costs
Every GLP-1's dosing schedule exists because jumping straight to a maintenance dose after a gap sharply increases GI side effects. Restarting means paying the lowest-dose price tier again for the multi-week climb back up - Wegovy's $349/mo starter tier, or Zepbound's $299/mo 2.5 mg tier - rather than whatever higher, more expensive (but also more effective) dose you had reached before stopping.
Most insurers already require periodic re-authorization (typically every 6-12 months) even for continuous use. A real gap in fills can push a renewal into a brand-new PA request instead - fresh BMI documentation, a fresh comorbidity check, sometimes a new step-therapy requirement - before your next fill is approved. Full PA documentation checklist here.
Manufacturer self-pay programs (NovoCare, LillyDirect) are not memberships - you are never locked out for pausing - but the posted price when you restart may not match what you paid before. Starter-tier promos have specific expiration dates that keep shifting; check current pricing rather than assuming your old rate still applies.
If cost is the reason you are considering stopping
Re-titration and PA-reset costs mean a full stop-and-restart cycle is usually more expensive than staying on a stable dose, even a lower maintenance one. If affordability is the actual driver, it is worth comparing a cheaper channel or dose adjustment against your prescriber before a full stop - the cheapest-GLP-1 comparison and savings-card guide cover the lower-cost paths on the same drug before you have to consider stopping altogether.
Frequently asked questions
Will I regain the weight if I stop a GLP-1?
The honest answer is "it depends which study you read, and both are right." Controlled trial data - most recently a January 2026 BMJ meta-analysis (Oxford, 9,341 participants across 37 studies) - found weight regain about 4x faster than after stopping a behavioral diet/exercise program, with weight returning to baseline in an average of 1.7 years and cardiometabolic benefits reversing even sooner. A separate March 2026 meta-regression (eClinicalMedicine, 48 studies) modeled the curve precisely: 60% of lost weight regained by 1 year, plateauing around 75% regained long-term (meaning roughly 25% of the loss persists indefinitely). But a March 2026 Cleveland Clinic real-world study of nearly 8,000 patients found much smaller regain in practice - about 0.5% of body weight at 1 year for the obesity-treatment group - because most people do not just stop and do nothing: 20% restarted the same drug, 27% switched to a different obesity medication, and 14% pursued lifestyle-only management. Trial data shows what happens if you stop and change nothing; real-world data shows what actually happens because most people do not stop and change nothing.
If I restart, do I have to re-titrate from the lowest dose again?
Almost always, yes, if you have been off the drug for more than a few weeks. Every GLP-1's dosing schedule (Wegovy 0.25 to 2.4 mg, Zepbound 2.5 to 15 mg, and similarly for Mounjaro and Ozempic) exists because jumping straight to a maintenance dose after a gap sharply increases GI side effects - nausea, vomiting - that the gradual titration is specifically designed to avoid. That means restarting is not just an emotional reset, it is a financial one: you are back at the lowest-dose pricing tier and the lowest-dose promotional pricing (where available) for another 2+ months before reaching the dose and cost you were at before you stopped. Concretely, restarting Wegovy means paying the $349/mo starter-tier price again during the multi-week climb back to 2.4 mg, and restarting Zepbound means starting back at the $299/mo 2.5 mg tier rather than whatever higher-dose tier you had reached.
Does stopping and restarting affect my insurance prior authorization?
Often, yes, and this is the cost surprise that catches insured patients most. Most insurers require periodic re-authorization even for continuous use (typically every 6-12 months, showing documented ongoing weight loss), and a gap in fills can trigger a full new prior-authorization request rather than a renewal - meaning fresh BMI documentation, a fresh comorbidity check, and in some cases a new step-therapy requirement, all before your next fill is approved. Practically: if you are pausing for a planned reason (travel, a supply gap, a temporary financial squeeze), ask your prescriber whether a "bridge" strategy - stretching your last fill, or a short manufacturer sample - can avoid a hard stop that resets your authorization clock. See the full prior-authorization playbook for what documentation to have ready before any restart request.
Do I lose my manufacturer savings card or self-pay pricing if I stop?
No, in the sense that manufacturer self-pay programs (NovoCare, LillyDirect) are direct-to-consumer purchase programs, not memberships you can be removed from - you can order again at any time at whatever the current posted price is, with no penalty tied to having previously paused. What is NOT guaranteed is that the price is unchanged: NovoCare and LillyDirect have both adjusted starter-tier promotional pricing and expiration dates during 2026 (see the Wegovy $199 promo, currently running through December 31, 2026), so a restart after a long gap may land on different pricing than when you left off. Savings cards tied to commercial insurance work similarly - the card itself does not expire from disuse, but it requires your insurance to still cover the drug, which can itself change while you were off it.
Is it cheaper to just stay on a lower maintenance dose instead of stopping?
For most patients on a self-pay or flat-copay plan, yes - continuing at a stable dose avoids both the re-titration cost climb described above and the risk of a prior-authorization reset. The math only flips if a lower dose meaningfully reduces your monthly cost tier (this varies by drug; check the specific dose-pricing breakdown on the calculator) and you and your prescriber agree a lower maintenance dose still holds your result. This is a clinical decision to make with your prescriber, not a pricing one - the cost information here is meant to inform that conversation, not replace it.
Sources
- West et al., "Weight regain and cardiometabolic effects after stopping GLP-1 receptor agonists," The BMJ, January 7, 2026.
- Budini et al., "Trajectory of weight regain after cessation of GLP-1 receptor agonists," eClinicalMedicine, March 4, 2026.
- Gasoyan et al., Cleveland Clinic real-world discontinuation study, published March 12, 2026 (newsroom.clevelandclinic.org).
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.